1-14 of 14
Johann de Bono
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes

Open Access
Elizabeth A. Coker, Adam Stewart, Bugra Ozer, Anna Minchom, Lisa Pickard, Ruth Ruddle, Suzanne Carreira, Sanjay Popat, Mary O'Brien, Florence Raynaud, Johann de Bono, Bissan Al-Lazikani, Udai Banerji
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (6): 1020–1029.
https://doi.org/10.1158/1535-7163.MCT-21-0442
Published: 01 June 2022
View articletitled, Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
Open the PDF for Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes in another window
Includes: Supplementary data
Journal Articles

Abstract PL03-01: Targeting DNA Repair and Defective DNA repair

Free
Johann de Bono
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): PL03-01.
https://doi.org/10.1158/1535-7163.TARG-19-PL03-01
Published: 01 December 2019
View articletitled, Abstract PL03-01: Targeting DNA Repair and Defective DNA repair
Journal Articles

Abstract B166: A RNA helicase siRNA screen to identify potential therapeutic targets in castration-resistant prostate cancer

Free
Hannah Wang, Emmanuel de Billy, Johann de Bono, Paul Workman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B166.
https://doi.org/10.1158/1535-7163.TARG-15-B166
Published: 01 December 2015
View articletitled, Abstract B166: A RNA helicase siRNA screen to identify potential therapeutic targets in castration-resistant prostate cancer
Journal Articles

Abstract A220: Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors.

Free
Joshua W. Henshaw, Huiyu Zhou, Ashleigh Herriott, Miranda Patterson, Evelyn W. Wang, Don Musson, Johann de Bono, Lida A. Mina, Ramesh K. Ramanathan, Charles O'Neill, Andrew Dorr, Nicola J. Curtin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A220.
https://doi.org/10.1158/1535-7163.TARG-13-A220
Published: 01 November 2013
View articletitled, Abstract A220: Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors.
Journal Articles

Abstract A164: Cardiac effects in a first-in-human (FIH), pharmacokinetic (PK), pharmacodynamic (PD) phase I trial of JNJ-26481585, a second-generation oral hydroxamate histone deacetylase inhibitor (HDACi), in patients with refractory cancer.

Free
Rebecca S. Kristeleit, Richard D. Baird, Balaji Venugopal, Duncan K. Wilkins, Fiona MacCormick, Roberta Granata, Donna Crawford, Julie Charlton, John Camm, Peter Hellemans, Nele Fourneau, Yusri Elsayed, Richard Cowan, Udai Banerji, Ruth Plummer, Jeff Evans, Johann de Bono
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A164.
https://doi.org/10.1158/1535-7163.TARG-11-A164
Published: 12 November 2011
View articletitled, Abstract A164: Cardiac effects in a first-in-human (FIH), pharmacokinetic (PK), pharmacodynamic (PD) phase I trial of JNJ-26481585, a second-generation oral hydroxamate histone deacetylase inhibitor (HDACi), in patients with refractory cancer.
Journal Articles

A Phase Ib study of telatinib (BAY 57-9352), a VEGFR-2 inhibitor, in combination with docetaxel in patients with advanced solid tumors

Free
Heather Shaw, Rhoda Molife, Vasilios Karavasilis, Teng Ong, Laura Tate, Peter Fong, Tim Yap, Rohit Lal, Catherine Ludwig, Erich Brendel, Olaf Christensen, Johann de Bono
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B13.
Published: 01 November 2007
View articletitled, A Phase Ib study of telatinib (BAY 57-9352), a VEGFR-2 inhibitor, in combination with docetaxel in patients with advanced solid tumors
Journal Articles

A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN®) in combination with radiation in patients with advanced malignancies.

Free
Dean Harris, Laura Vidal, Alan Melcher, Kate Newbold, Alan Anthony, Vasilios Karavasilis, Roshan Agarwal, Chris White, Katie Twigger, Matt Coffey, Karl Mettinger, Brad Thompson, Hardev Pandha, Johann De-Bono, Kevin Harrington
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B81.
Published: 01 November 2007
View articletitled, A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN®) in combination with radiation in patients with advanced malignancies.
Journal Articles

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent administered as an infusion over 24 h every 21 days in patients with solid tumors

Free
Richard Baird, Andre Planting, Alison Reid, Jos Kitzen, Sarah Reade, Paul Clarke, Lyndsey Welsh, Luis Lopez Lazaro, Begona de las Heras, Ian Judson, Cesar Pico, Paul Workman, Ferry Eskens, Stan Kaye, Johann de Bono, Jaap Verweij
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A141.
Published: 01 November 2007
View articletitled, Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent administered as an infusion over 24 h every 21 days in patients with solid tumors
Journal Articles

Potential Utilities of the Study of Circulating Tumor Cells in the Design of Clinical Trials of Molecularly Targeted Drugs

Free
Johann de Bono
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): PL08-01.
Published: 01 November 2007
View articletitled, Potential Utilities of the Study of Circulating Tumor Cells in the Design of Clinical Trials of Molecularly Targeted Drugs
Journal Articles

An exploration of the ability of DCE-CT scans to evaluate blood flow in an open, pharmacokinetic (PK) and mass balance study of 14[C]-cediranib

Free
Alison Reid, Adrian Tang, James Spicer, Elisa Gallerani, Dorothy Mears, Heather Shaw, Vasilios Karavasilis, Sarah Settatree, Timothy Yap, Cheryl Marriot, Thomas Puchalski, Mike Harrison, Jo Naish, Helen Mann, Johann De-Bono
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B259.
Published: 01 November 2007
View articletitled, An exploration of the ability of DCE-CT scans to evaluate blood flow in an open, pharmacokinetic (PK) and mass balance study of 14[C]-cediranib
Journal Articles

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: The Royal Marsden Hospital (RMH) experience.

Free
Hendrik-Tobias Arkenau, Joo Ern Ang, David Olmos, Craig Carden, Sophie Postel-Vinay, Debs Sarker, Claire Barlow, Johann de Bono, Ian Judson, Stan Kaye
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A154.
Published: 01 November 2007
View articletitled, Clinical outcome and prognostic factors for patients treated within the context of a phase I study: The Royal Marsden Hospital (RMH) experience.
Journal Articles

Safety, tolerability and preliminary efficacy of the anti-IGF-IR monoclonal antibody CP-751,871 in patients with sarcomas and adrenocortical tumors.

Free
David Olmos, Rhoda Molife, Scott Okuno, Frank Worden, Gary Hammer, Timothy Yap, Heather Shaw, Scott Schuetze, Luisa Roberts, Antonio Gualberto, Johann de-Bono, Paul Haluska
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A63.
Published: 01 November 2007
View articletitled, Safety, tolerability and preliminary efficacy of the anti-IGF-IR monoclonal antibody CP-751,871 in patients with sarcomas and adrenocortical tumors.
Journal Articles

Selective inhibition of CYP17 with abiraterone acetate is well tolerated and results in a high response rate in castration-resistant prostate cancer (CRPC)

Free
Gerhardt Attard, Alison Reid, Rajesh Sinha, Rhoda Molife, Florence Raynaud, Mitch Dowsett, Mary Barrett, Emilda Thompson, Timothy Yap, Sarah Settatree, Vanessa Martins, Christopher Parker, David Dearnaley, Elizabeth Folkerd, Gloria Lee, Johann De Bono
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B73.
Published: 01 November 2007
View articletitled, Selective inhibition of CYP17 with abiraterone acetate is well tolerated and results in a high response rate in castration-resistant prostate cancer (CRPC)
Journal Articles

A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors.

Free
Rhoda Molife, James Lee, Daniel Petrylak, George Blumenschein, Ulrik Lassen, Jayme Clark, Timothy Yap, Elin Rowen, Jooern Ang, Elizabeth Crowley, Anne Clarke, Thomas Hawthorne, Peter Buhl-Jensen, Johann de Bono, Wm Kelly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B134.
Published: 01 November 2007
View articletitled, A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors.